Table 2.

Changes in antibody levels in patients with HPV-positive oropharyngeal cancer over time¹

Overall study population					Subset: ISH HPV16-positive subjects
Serology	N	Mean ± SE2	P-value3	P-trend3	N	Mean ± SE2	P-value3	P-trend3
E1				0.066				0.168
Pre-Treatment	43	−0.508 ± 0.223	-		31	−0.323 ± 0.228	-
Early Post-Treatment	29	−0.559 ± 0.235	0.730		21	−0.326 ± 0.242	0.985
Late post-treatment	37	−0.816 ± 0.227	0.024		27	−0.584 ± 0.232	0.082
E2				0.166				0.019
Pre-Treatment	43	0.032 ± 0.191	-		31	0.296 ± 0.166	-
Early Post-Treatment	29	0.047 ± 0.200	0.896		21	0.199 ± 0.170	0.212
Late post-treatment	37	−0.148 ± 0.194	0.092		27	0.092 ± 0.167	0.005
E6				0.001				<0.0001
Pre-Treatment	43	−1.272 ± 0.148	-		31	−1.175 ± 0.143	-
Early Post-Treatment	29	−1.484 ± 0.163	0.114		21	−1.471 ± 0.149	0.001
Late post-treatment	37	−1.736 ± 0.153	0.0003		27	−1.594 ± 0.145	<0.0001
E7				<0.0001				<0.0001
Pre-Treatment	43	−0.381 ± 0.187	-		31	−0.265 ± 0.188	-
Early Post-Treatment	29	−0.692 ± 0.201	0.031		21	−0.530 ± 0.194	0.006
Late post-treatment	37	−1.049 ± 0.192	<0.0001		27	−0.822 ± 0.190	<0.0001

¹This analysis was restricted to subjects with available pre-treatment serology measurements

²Estimated log-transformed mean. SE denotes standard error.

³Comparison relative to pre-treatment measurements based on linear mixed effects models taking into account the within-subject correlation